SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel...
Hence then, the article about carsgen presents preliminary results on satri cel for adjuvant therapy of pancreatic cancer at esmo congress 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025 )
Also on site :
- GCE Global Solutions Corp. Announces Strategic Acquisition of GCE Payroll Advisers Inc. to Strengthen Global EOR and Payroll Platform
- Trump Wants To”Unleash Hell” In 2026; POTUS Tries To Go Full Maximus With A Misguided ‘Gladiator’ Flex
- Parents of Campbell Hall student killed in the school’s parking lot file wrongful death suit